EMA says it will consider conditional approval for NASH drugs using intermediate endpoints

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsEuropePharmaceuticalsPreclinical studyProduct developmentRegulatory Intelligence/PolicyResearch, Design and Development